Literature DB >> 7522242

Membranous lipodystrophy: secondary type.

S I Chun1, K Y Chung.   

Abstract

BACKGROUND: A peculiar type of fat necrosis was noted in some patients with various skin diseases.
OBJECTIVE: We attempted to develop a classification of membranous lipodystrophy combining the results of our study and a review of other articles.
METHODS: Five cases of skin diseases with membranous lipodystrophy were studied and their clinical and histopathologic features were analyzed. Previous reports of similar findings were reviewed.
RESULTS: Membranous lipodystrophic changes were noted in morphea profunda, lupus panniculitis, and factitial ulcer. Microcysts were formed by the coalescence of the destroyed fat cells and were lined by amorphous, eosinophilic material. Some of the linings had a crenelated appearance. Microgranules were found in the histiocytes and in the hyalinized collagen stroma. The linings and microgranules stained positively with periodic acid-Schiff, were resistant to diastase, and also stained with Sudan black B.
CONCLUSION: We propose the use of the term secondary membranous lipodystrophy to describe the local subcutaneous membranous lipodystrophic change that occurs as a result of other skin diseases, in contrast to primary idiopathic membranous lipodystrophy, which occurs without any antecedent factors.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7522242     DOI: 10.1016/s0190-9622(94)70223-3

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  2 in total

Review 1.  Nasu-Hakola syndrome: polycystic lipomembranous osteodysplasia with sclerosing leucoencephalopathy and presenile dementia.

Authors:  A Verloes; P Maquet; B Sadzot; M Vivario; A Thiry; G Franck
Journal:  J Med Genet       Date:  1997-09       Impact factor: 6.318

Review 2.  Membranous lipodystrophy: case report and review of the literature.

Authors:  Fatma Akpinar; Ektan Demir; Duygu Dusmez Apa
Journal:  An Bras Dermatol       Date:  2015 May-Jun       Impact factor: 1.896

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.